Skip to main content
Home
FULL MENU Close Menu
Home
Home

Mark S. Lesney, PhD

News

Antihistamines synergistically induce CLL cell death with TK inhibitors

Author:
Mark S. Lesney, PhD
Publish date: August 26, 2020

Over-the-counter antihistamines induced synergistic cytotoxicity with TK inhibitors.

  • Read More

News

Polygenic risk score may predict VTE in adolescents, but not adults, with ALL

Author:
Mark S. Lesney, PhD
Publish date: August 14, 2020

A genetic risk score predicted which acute lymphoblastic leukemia–affected adolescents were more at risk of a...

  • Read More

News

Elotuzumab-based therapy may benefit post-transplant response in multiple myeloma

Author:
Mark S. Lesney, PhD
Publish date: August 12, 2020

Elotuzumab-based maintenance may deepen response post transplant in MM and can be safely administered in older...

  • Read More

News

BALL score predicts benefit from ibrutinib therapy in relapsed/refractory CLL patients

Author:
Mark S. Lesney, PhD
Publish date: August 11, 2020

The BALL score outperformed three other scores in providing the best prediction of an overall survival benefit...

  • Read More

Opinion

Chronicles of cancer: A history of mammography, part 1

Author:
Mark S. Lesney, PhD
Publish date: August 7, 2020

Tied to the rise of technology and the women's rights movement, the story of mammography is a touchstone for the history of cancer screening and...

  • Read More

News

Posaconazole prophylaxis was effective in children with ALL undergoing chemotherapy

Author:
Mark S. Lesney, PhD
Publish date: August 7, 2020

Targeted posaconazole prophylaxis was effective in preventing invasive fungal infection in children with ALL undergoing induction chemotherapy.

  • Read More

News

MM patients with concurrent AL show poor survival when coupled to cardiac dysfunction

Author:
Mark S. Lesney, PhD
Publish date: July 23, 2020

Cardiac dysfunction is a major determinant of poor survival in multiple myeloma patients with concurrent light chain amyloidosis.

  • Read More

News

HSCT or systemic treatment should be offered to HIV+ patients with lymphoma

Author:
Mark S. Lesney, PhD
Publish date: July 16, 2020

Patients with lymphoma and HIV infection benefit from systemic or stem cell therapy, but with worse outcomes...

  • Read More

News

Heavy menstrual bleeding difficult to control in young patients with inherited platelet disorders

Author:
Mark S. Lesney, PhD
Publish date: July 10, 2020

Consensus and a broadly effective treatment for heavy menstrual bleeding was not found among the patients with inherited platelet function...

  • Read More

News

Transitioning regimen may prolong proteasome inhibitor–based therapy for MM

Author:
Mark S. Lesney, PhD
Publish date: July 9, 2020

Transitioning from parenteral bortezomib-based induction to all-oral ixazomib-lenalidomide-dexamethasone increased PI-based treatment adherence/...

  • Read More

News

FDA approves selinexor for relapsed/refractory DLBCL

Author:
Mark S. Lesney, PhD
Publish date: June 23, 2020

Selinexor is approved for adults with relapsed/refractory DLBCL, including DLBCL arising from follicular...

  • Read More

News

Oxidatative stress–related genetic variant tied to stroke risk in sickle cell patients

Author:
Mark S. Lesney, PhD
Publish date: June 23, 2020

SOD2 Val16Ala polymorphism may represent a simple and inexpensive alternative for identifying sickle cell patients at risk of stroke.

  • Read More

News

First-in-kind anti-CD47 antibody shows promise for MDS and AML treatment

Author:
Mark S. Lesney, PhD
Publish date: June 19, 2020

Magrolimab/azactydine (AZA) improved outcomes in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS...

  • Read More

News

Subcutaneous hep A vaccination as effective as intramuscular for bleeding disorder patients

Author:
Mark S. Lesney, PhD
Publish date: June 12, 2020

Subcutaneous hepatitis A vaccination is as effective and may be safer for patients with bleeding disorders....

  • Read More

News

Added rituximab was effective in children and adolescents with high-risk B-cell NHL

Author:
Mark S. Lesney, PhD
Publish date: June 3, 2020

Adding rituximab to chemotherapy was effective in children and adolescents with high-risk, high-grade, mature B-...

  • Read More

Pages

  • « first
  • 1
  • 2
  • 3
  • 4
  • last »

Privacy Policy

Do Not Sell My Personal Information

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close